2025

Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial
Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, Rüssel J, Schuch G, Wierecky J, Sinn M, Tintelnot J, Petersen C, Rothkamm K, Vettorazzi E, Binder M
CLIN COLORECTAL CANC. 2025;24(1):11-17.

Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran S, Reinacher-Schick A, Pink D, Bokemeyer C, Sinn M, Lindig U, Hinke A, Hegewisch-Becker S, Stein A, Binder M
CANCER IMMUNOL RES. 2025;13(2):200-209.

Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot J, Xu Y, Lesker T, Schönlein M, Konczalla L, Giannou A, Pelczar P, Kylies D, Puelles V, Bielecka A, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring T, Trajkovic-Arsic M, Siveke J, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu F, Güngör C, Stein A, Izbicki J, Bokemeyer C, Sinn M, Kimmelman A, Huber S, Gagliani N
NATURE. 2025;641(8065):E12-E13.

2024

Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments
Ristow I, Well L, Wiese N, Warncke M, Tintelnot J, Karimzadeh A, Koehler D, Adam G, Bannas P, Sauer M
CANCERS. 2024;16(5):.

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
Schmoll H, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, Goekkurt E, Kaiser U, Hoeffkes H, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Roll C, Bokemeyer C, Steighardt J, Cygon F, Ibach S, Stein A, Tintelnot J
BRIT J CANCER. 2024;130(2):233-241.

Diet and immune response: how today's plate shapes tomorrow's health
Siracusa F, Tintelnot J, Cortesi F, Gagliani N
TRENDS IMMUNOL. 2024;45(1):4-10.

2023

Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma
Artzenroth J, Tintelnot J, Haag G, Gökkurt E, Steffens J, Stein A
ONCOL RES TREAT. 2023;46(7-8):320-325.

IL-22BP controls the progression of liver metastasis in colorectal cancer
Giannou A, Kempski J, Zhang T, Lücke J, Shiri A, Zazara D, Belios I, Machicote A, Seeger P, Agalioti T, Tintelnot J, Sagebiel A, Tomczak M, Bauditz L, Bedke T, Kocheise L, Mercanoglu B, Fard-Aghaie M, Giorgakis E, Lykoudis P, Pikouli A, Grass J, Wahib R, Bardenhagen J, Brunswig B, Heumann A, Ghadban T, Duprée A, Tachezy M, Melling N, Arck P, Stringa P, Gentilini M, Gondolesi G, Nakano R, Thomson A, Perez D, Li J, Mann O, Izbicki J, Gagliani N, Maroulis I, Huber S
FRONT ONCOL. 2023;13:1170502.

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Bardenhagen J, Stern L, Tintelnot J, Schönlein M, Sinn M, van der Leest P, Simon R, Heumann A, Izbicki J, Pantel K, Wikman H, Uzunoglu F
CLIN CHEM. 2023;69(3):295-307.

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
Paschold L, Stein A, Thiele B, Tintelnot J, Henkes S, Coith C, Schultheiß C, Pantel K, Riethdorf S, Binder M
J IMMUNOTHER CANCER. 2023;11(6):.

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)
Tintelnot J, Stein A, Al-Batran S, Ettrich T, Götze T, Grün B, Haag G, Heuer V, Hofheinz R, Homann N, Bröring T, Cruz M, Kurreck A, Lorenzen S, Moosmann N, Müller C, Schuler M, Siegler G, Binder M, Gökkurt E
FRONT ONCOL. 2023;13:1272175.

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot J, Xu Y, Lesker T, Schönlein M, Konczalla L, Giannou A, Pelczar P, Kylies D, Puelles V, Bielecka A, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring T, Trajkovic-Arsic M, Siveke J, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu F, Güngör C, Stein A, Izbicki J, Bokemeyer C, Sinn M, Kimmelman A, Huber S, Gagliani N
NATURE. 2023;615(7950):168-174.

Calcium channel β3 subunit regulates ATP-dependent migration of dendritic cells
Woo M, Ufer F, Sonner J, Belkacemi A, Tintelnot J, Sáez P, Krieg P, Mayer C, Binkle-Ladisch L, Engler J, Bauer S, Kursawe N, Vieira V, Mannebach S, Freichel M, Flockerzi V, Vargas P, Friese M
SCI ADV. 2023;9(38):.

CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis
Zhang T, Wahib R, Zazara D, Lücke J, Shiri A, Kempski J, Zhao L, Agalioti T, Machicote A, Giannou O, Belios I, Jia R, Zhang S, Tintelnot J, Seese H, Grass J, Mercanoglu B, Stern L, Scognamiglio P, Fard-Aghaie M, Seeger P, Wakker J, Kemper M, Brunswig B, Duprée A, Lykoudis P, Pikouli A, Giorgakis E, Stringa P, Lausada N, Gentilini M, Gondolesi G, Bachmann K, Busch P, Grotelüschen R, Maroulis I, Arck P, Nakano R, Thomson A, Ghadban T, Tachezy M, Melling N, Achilles E, Puelles V, Nickel F, Hackert T, Mann O, Izbicki J, Li J, Gagliani N, Huber S, Giannou A
ONCOIMMUNOLOGY. 2023;12(1):2269634.

2022

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes S, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran S, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M
JAMA ONCOL. 2022;8(8):1150-1158.

Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
Tintelnot J, Ristow I, Sauer M, Simnica D, Schultheiß C, Scholz R, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Dörfel S, Al-Batran S, Karthaus M, Pelzer U, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M, Stein A
FRONT ONCOL. 2022;12:.

2021

A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer
Moehler M, Michel M, Stein A, Trojan J, Marquardt J, Tintelnot J, Waidmann O, Weinmann A, Woerns M, Schroeder H, Maenz M, Foerster F
FUTURE ONCOL. 2021;17(25):3309-3319.

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Dörfel S, Al-Batran S, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M
J IMMUNOTHER CANCER. 2021;9(7):.

2020

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild J, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran S, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A
BMC CANCER. 2020;20(1):503.

2019

Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies
Tintelnot J, Baum N, Schultheiss C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schütze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M
MOL CANCER THER. 2019;18(4):823-833.

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M
FRONT ONCOL. 2019;9:1559.

Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot J, Stein A
WORLD J GASTROENTERO. 2019;25(29):3920-3928.

Arc/Arg3.1 defines dendritic cells and Langerhans cells with superior migratory ability independent of phenotype and ontogeny in mice
Tintelnot J, Ufer F, Engler J, Winkler H, Lücke K, Mittrücker H, Friese M
EUR J IMMUNOL. 2019;49(5):724-736.

2016

Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation
Ufer F, Vargas P, Engler J, Tintelnot J, Schattling B, Winkler H, Bauer S, Kursawe N, Willing A, Keminer O, Ohana O, Salinas-Riester G, Pless O, Kuhl D, Friese M
SCI IMMUNOL. 2016;1(3):eaaf8665.

Letzte Aktualisierung aus dem FIS: 18.08.2025 - 00:39 Uhr